Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00584974 · ClinicalTrials.gov registry record · Phase 2

A Safety, Efficacy and Tolerability Study of SEP-225289

A Phase 2 study of Depressive Disorder, Major, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 2
Development phase
523
Enrollment target
20
Study locations

NCT00584974 is a Phase 2 study of Depressive Disorder, Major that has completed, run by Sumitomo Pharma America. The registered enrollment target is 523 participants, above the 232-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (125% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00584974, a Phase 2 study of Depressive Disorder, Major, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 2
Development phase
523 participants
Enrollment target
20
Study locations

Study Summary

To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder

Conditions Studied

Depressive Disorder, Major

Interventions

  • DRUG placebo
  • DRUG SEP-225289
  • DRUG Venlafaxine

Study Locations (20)

California

  • - Arcadia
  • - Beverly Hills
  • - Costa Mesa
  • - Garden Grove
  • - Glendale
  • - Irvine
  • - Lafayette
  • - Oceanside
  • - San Diego
  • - Upland

Florida

  • - Bradenton
  • - Fort Myers
  • - Jacksonville
  • - Lauderhill
  • - Maitland
  • - North Miami

Colorado

  • - Denver
  • - Denver

Arkansas

  • - Little Rock

Connecticut

  • - New Britain

Trial Details

FieldValue
Enrollment Target 523 participants
Start Date 2007-12
Est. Completion 2009-05
Phase Phase 2

Sponsor

Sumitomo Pharma America

168 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00584974

The ClinicalTrials.gov registry entry for NCT00584974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 523 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 232-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (125% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00584974 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT00584974 about?

NCT00584974 is a clinical study titled "A Safety, Efficacy and Tolerability Study of SEP-225289". To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder

What is the current status of trial NCT00584974?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 523 participants. The study started on 2007-12. Estimated completion is 2009-05.

What conditions does trial NCT00584974 study?

This clinical trial studies the following conditions: Depressive Disorder, Major.

What interventions are being tested in trial NCT00584974?

The interventions under investigation include: placebo (DRUG), SEP-225289 (DRUG), Venlafaxine (DRUG).

Who is sponsoring clinical trial NCT00584974?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00584974 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depressive Disorder, Major

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depressive Disorder, Major

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.